17-92 in variety of human cancers and disorders. [10] [11] [12] Genetic studies demonstrated that miR-17-92 is indispensible for mouse development and cell proliferation, and miR-17-92 mutant mice die postnatally, displaying defects in lung, hearts,
T he adult mammalian heart has limited capability to regenerate itself after the loss of mature cardiomyocytes because of a variety of pathological conditions such as myocardial infarction. It is generally conceived that postmitotic cardiomyocytes in adult hearts exit from the cell cycle and stop cell proliferation. 1, 2 However, the hearts of adult zebrafish can undergo cardiac regeneration without scar formation after resection of ventricle, primarily through cardiomyocyte proliferation. [3] [4] [5] [6] Intriguingly, a recent report demonstrated that surgical resection of the ventricular apex in newborn mice stimulates the proliferation of cardiomyocytes and repairs the damaged heart, but the mouse heart loses this regenerative potential within 7 days of its postnatal life and it is not clear how the regenerative potential is lost in the adult hearts. 7 To date, the molecular mechanism and regulatory pathways that control adult cardiomyocyte proliferation and cardiac regeneration remain largely unknown.
MicroRNAs (miRNAs) are a class of ≈22 nt noncoding RNAs that regulate the expression of protein-coding genes post-transcriptionally. More than 1000 human miRNAs have been identified, however the biological functions of many of them remain unknown. miR-17-92 cluster was initially reported as a human oncogene and named oncomir1. 8, 9 Numerous reports have documented the expression of miR-and others. [13] [14] [15] We hypothesized that miR-17-92 regulates the proliferation of cardiomyocytes. In this study, we tissuespecifically overexpress or delete the miR-17-92 cluster in cardiomyocytes in transgenic or knockout mice and found that miR-17-92 participates in the regulation of cardiomyocyte proliferation in embryonic, postnatal, and adult hearts.
Methods
Cell culture, quantitative RT-PCR analyses, Western blot analyses, histologic assessments, and immunochemistry were performed according to routine protocols. Details of Materials and Methods are provided in the Online Data Supplement.
Statistics
Values are reported as means±SEM unless indicated otherwise. The 2-tailed Mann-Whitney U test was used for comparing 2 means (Prism, GraphPad). Values of P<0.05 were considered statistically significant.
Results

miR-17-92 Is Required For Cardiomyocyte Proliferation in Embryonic and Postnatal Hearts
We crossed the miR-17-92 flox/flox mice 15 with Nkx2.5-Cre mice, in which the expression of Cre recombinase is under the control of the cardiac-specific Nkx2.5 gene, to delete miR-17-92 in embryonic, postnatal, and adult hearts (Online Figure IA ). We found that cardiac-specific miR-17-92 mutant mice (named miR-17-92 cKO) are slightly underrepresentative (20.3%) at weaning age, suggesting that cardiac-specific deletion of miR-17-92 resulted in partial embryonic lethality (Online Figure IB) . We confirmed that the expression of miR-17-92 miRNAs was significantly reduced in the hearts of mutant mice (Online Figure II) .
The hearts of postnatal miR-17-92 cKO mice seem to be smaller than that of their littermate controls ( Figure 1A) . We examined the proliferation of cardiomyocytes in miR-17-92 cKO hearts, using immunostaining for phosphorylated histone H3 (pH3), which marks mitosis, and we found that there is less proliferation of cardiomyocytes in postnatal hearts of miR-17-92 cKO mice ( Figure 1B and 1C; Online Figure  III ). Quantitative analyses confirmed substantial decrease in total numbers of pH3-positive cardiomyocytes in miR-17-92 cKO hearts ( Figure 1D ). We also observed a decrease in cardiomyocyte proliferation in miR-17-92 heterozygous hearts ( Figure 1D ). We asked whether loss of miR-17-92 affected the survival of cardiomyocytes. We performed terminal deoxynucleotidyl transferase dUTP nick end labeling assay to measure apoptosis and observed no change in terminal deoxynucleotidyl transferase dUTP nick end labeling signals in postnatal hearts of miR-17-92 cKO mice when compared with controls (Online Figure IV) .
Most miR-17-92 cKO mice survived to adulthood, and we next investigated miR-17-92 loss-of-function phenotype in adult hearts. There was no obvious difference in the gross cardiac morphology of the miR-17-92 cKO and their littermate control mice (Online Figure VA) . The heart weight to body weight ratio was not altered in miR-17-92 cKO mice ( Figure 1E ). However, there seemed to be a compensatory cardiomyocyte hypertrophy in these hearts (Online Figure  VB) . We used Langendorf perfusion method to isolate cardiomyocytes from adult hearts. Freshly isolated adult cardiomyocytes were stained with α-actinin to label cardiomyocytes; pan-cadherin to recognize desmosomes. Reconstructed confocal images clearly indicate that the majority of isolated cardiomyocytes were intact ( Figure 1F ). Quantitative analysis indicated a substantial decrease in the total numbers of cardiomyocytes in the hearts of miR-17-92 cKO mice ( Figure 1G and 1H). Quantitative measurement of the size of isolated adult cardiomyocytes showed that the size of cardiomyocytes was increased in the heart of miR-17-92 cKO mice ( Figure 1I ), consistent with the idea that increased size of cardiomyocytes compensates for the reduction of total numbers of cardiomyocytes in mutant hearts. Terminal deoxynucleotidyl transferase dUTP nick end labeling assays detected no difference in apoptosis in the heart of 8-month-old miR-17-92 cKO mice when compared with controls (Online Figure IV) . We examined the cardiac function, using echocardiography, and found decreased in ventricle wall thickness, increased in ventricle systolic diameter, and decreased in cardiac function in miR-17-92 cKO mice when compared with their littermate controls (Online Figure VI ; Online Table I ). Together, these results indicate that miR-17-92 is required for cardiomyocyte proliferation and normal cardiac function in postnatal and adult hearts.
miR-17-92 Is Sufficient to Induce Cardiomyocyte Proliferation in Embryonic and Postnatal Hearts
Having demonstrated that miR-17-92 is required for cardiomyocyte proliferation in embryonic and postnatal hearts, we next tested whether overexpression of miR-17-92 was sufficient to induce cardiomyocyte proliferation. We generated cardiac-specific conditional transgenic mice to overexpress miR-17-92 in the heart. We first bred the floxed miR-17-92 knock-in (KI) allele, in which a loxP-flanked Neo-STOP cassette was inserted upstream of the bicistronic human miR-17-92 cluster and knocked into the Rosa26 locus (named miR-17-92 KI), 16 with the Nkx2.5-Cre mice to achieve the overexpression of miR-17-92 in embryonic and postnatal hearts (Online Figure VII) . The hearts of cardiac-specific miR-17-92 transgenic mice (named miR-17-92 TG nkx2.5 ) were dramatically enlarged ( Figure 2A ). Histological section revealed that the ventricle wall was substantially thickened in the hearts of miR-17-92 TG nkx2.5 mice (Figure 2A ). The heart was hyperplasia and trabeculas were highly condensed and packed (Figure 2A , bottom). There was no evidence of cardiomyocyte hypertrophy, and the size of cardiomyocytes is comparable between miR-17-92 TG nkx2.5 and control mice. The increase of cardiomyocyte numbers resulted from an increase in cardiomyocyte proliferation. We used Figure VIII ). Concordantly, there was a significant increase in heart/body weight ratios in miR-17-92 TG nkx2.5 mice ( Figure 2E ).
Next, we generated transgenic mice to overexpress miR-17-92 predominantly in postnatal and adult cardiomyocytes. We bred miR-17-92 KI mice with α-MHC-Cre transgenic mice, in which the expression of Cre recombinase is directed by the cardiac-specific α-MHC (Myh6) promoter, to generate cardiac-specific miR-17-92 transgenic mice (named miR-17-92 TG MHC ). We observed about 2 to 5 folds higher miR-17-92 expression in transgenic hearts (Online Figure  IX) . Most miR-17-92 TG MHC mice survived to adulthood (Online Figure X) . The hearts of the miR-17-92 TG MHC mice were substantially enlarged ( Figure 3A) , and the heart/ body weight ratio was significantly increased in these mice ( Figure 3B ). Cardiac-specific overexpression of miR-17-92 increased the thickness of ventricle wall in transgenic mice ( Figure 3C ; Online Table II ). Quantitative measurement of cardiomyocyte cell size and cell number of the miR-17-92 TG MHC hearts demonstrated a substantial increase in the cell number in the heart of miR-17-92 TG MHC mice, whereas the size of cardiomyocyte was not changed (Online Figure XI) . We isolated cardiomyocytes from adult hearts using Langendorf isolation method and determined that there was substantial increase in total cardiomyocyte numbers in miR-17-92 TG MHC hearts ( Figure 3D and 3E ). Intriguingly, we found that there is an increase in total numbers of mono-nucleus cardiomyocytes and decrease in binuclei cardiomyocytes in miR-17-92 TG MHC hearts ( Figure 3F ; Online Figure XII) . Consistent with the increase in the cell numbers, the proliferation of cardiomyocytes, marked by pH3, was enhanced in miR-17-92 TG MHC hearts ( Figure 3G and 3H; Online Figure XIII ). Increased cell proliferation in miR-17-92 TG MHC hearts was further confirmed by 5-ethynyl-2′-deoxyuridine (EdU) incorporation and quantification ( Figure 3I and 3J ). Finally, we stained cardiomyocytes with aurora B to detect cytokinesis. We observed an increase in aurora B signals in postnatal days 5 and 15 hearts of the miR-17-92 TG MHC mice (Online Figure  XIV) . Z-stack confocal images confirmed that positive aurora B signals are located in cardiomyocytes (Online Figure XIV) .
miR-17-92 Induces Cardiomyocyte Proliferation in Adult Hearts and in Response to Injury
The above data indicate that overexpression of miR-17-92 was sufficient to induce cardiomyocyte proliferation in embryonic, neonatal and adult hearts. To further determine the function of miR-17-92 in the proliferation of postmitotic cardiomyocytes in adult hearts more definitely, we used an inducible system to overexpress miR-17-92 in cardiomyocytes of 4-month-old mice. We bred the miR-17-92 KI mice with the α-MHC-MerCreMer transgenic mice in which the Myh6 promoter directs the expression of a tamoxifen-inducible Cre recombinase in cardiomyocytes. We induced miR-17-92 overexpression in adult cardiomyocytes by activating tamoxifen-inducible Cre recombinase (see Materials and Methods). We confirmed cardiac-specific overexpression of members of the miR-17-92 cluster in the hearts of miR-17-92 transgenic mice (named miR-17-92 TG MerCreMer ) after tamoxifen administration (Online Figure XV) . The hearts of miR-17-92 TG MerCreMer mice were substantially larger than that of the littermate controls after miR-17-92 overexpression ( Figure 4A ). Tissue sections revealed an increase in wall thickness and left ventricle dimension ( Figure 4A ). We examined whether overexpression of miR-17-92 in adult cardiomyocytes could induce cell proliferation. Using EdU incorporation assay, we found marked increase in the EdU incorporation in the cardiomyocytes of 6-month-old miR-17-92 TG MerCreMer hearts ( Figure 4B ; Online Figure XVI) . We isolated cardiomyocytes from the hearts of miR-17-92 TG MerCreMer and control mice to determine the total numbers of cardiomyocytes and found that overexpression of miR-17-92 substantially increased total cardiomyocyte number in adult hearts ( Figure 4C ). Quantitative measurement of the size of isolated adult cardiomyocytes showed that the size of cardiomyocytes was reduced in the heart of miR-17-92 TG MerCreMer mice (Online Figure XVII) . To further confirm the cardiomyocyte proliferation in the miR-17-92 TG MerCreMer hearts, we used pH3 to mark proliferating cardiomyocytes and found that overexpression of miR-17-92 is sufficient to enhance cardiomyocyte proliferation in adult hearts ( Figure 4D and 4E) .
To test whether this cluster of miRNAs is involved in the regulation of cardiomyocyte proliferation and cardiac repair in response to injury, we introduced myocardial infarction (MI) by coronary artery occlusion (Online Figure XVIII) . MI results in massive cardiomyocyte death, cardiac hypertrophy, fibrosis, and cardiac remodeling. We found that overexpression of miR-17-92 in adult cardiomyocytes modestly protected the heart from MI-induced injury ( Figure 4F ). There is an increase of cardiac function, as measured by echocardiography and documented as fractional shortening, in miR-17-92 TG MerCreMer mice when compared with controls ( Figure 4F and 4G; Online Table III ). Quantification confirmed the decrease in the size of scar in the hearts of miR-17-92 TG MerCreMer mice after MI ( Figure 4H ). Using EdU incorporation assay, we found marked increase in the EdU incorporation in the cardiomyocytes of border zone of miR-17-92 TG MerCreMer hearts ( Figure 4I ). We asked whether apoptosis is affected in miR-17-92 transgenic hearts. Terminal deoxynucleotidyl transferase dUTP nick end labeling assays showed no difference in apoptosis between miR-17-92 transgenic and control hearts in response to MI injury (Online Figure XIX) . Similarly, we treated both miR-17-92 transgenic and control mice with doxorubicin, a cancer drug which causes heart failure as side effect, to induce stress. We found that overexpression of miR-17-92 modestly induces cardiomyocyte proliferation on doxorubicin treatment.
miR-17-92 Is Sufficient to Induce Neonatal Cardiomyocyte Proliferation In Vitro
To test whether members of this cluster of miRNAs play a similar role in cardiomyocyte proliferation in vitro, we transfected neonatal rat cardiomyocytes with mimics or inhibitors of each member of the miR-17-92 cluster and assayed cardiomyocyte proliferation. 17, 18 We used cardiomyocytes isolated from postnatal day 1 (P1) hearts, in which cardiomyocytes were still undergoing active proliferation. 7 After it was transfected with miR-17-92 mimics ( Figure 5A ) or inhibitors ( Figure 5B ), the cell culture was then incubated with EdU to label DNA synthesis and cell proliferation. Indeed, we found that miR-17-92 mimics, especially miR-19a/b family, potently induce cardiomyocyte proliferation ( Figure 5A and 5C). Conversely, inhibition of members of the miR-17-92 cluster, in particular miR-19a/b, substantially reduced cardiomyocyte proliferation, evidenced by the decrease of EdU signal and the reduction of total cardiomyocyte numbers when compared with controls ( Figure 5B and 5D ). We applied aurora B staining to detect cytokinesis in these cells ( Figure 5E ). Quantitative analysis confirmed a significant increase in aurora B signal after miR-19a/b treatment ( Figure 5F ). Furthermore, we treated postnatal day 4 (P4) cardiomyocytes, in which cell proliferation starts to diminish, with miR-17-92 mimics, and found that miR-17-92 mimics, miR-19a/b in particular, significantly induced EdU incorporation (Online Figure XXA) . This observation is further confirmed by quantitative analyses (Online Figure XXB) . We examined the expression of cyclin-dependent kinase 1, a highly conserved serine/threonine kinase involved in cell-cycle progression, 19 in miR-17-92 mimic-treated cardiomyocytes. Consistent with the view that miR-17-92 induced cardiomyocyte proliferation, we found that miR-17-92 induced the expression of cyclin-dependent kinase 1 in cardiomyocytes ( Figure 5G ).
Next, we isolated neonatal cardiomyocytes from miR-17-92 KI mice. Cultured cardiomyocytes were infected with Ad-cTNT-Cre to induce the overexpression of miR-17-92 ( Figure 5H ). We found that overexpression of miR-17-92 in mouse neonatal cardiomyocytes, but not the cells treated with the control Ad-lacZ, dramatically enhanced the incorporation of EdU, indicating an increase in cardiomyocyte proliferation ( Figure 5H and 5I ). Together, our data demonstrate that miR-17-92 mimics induce, whereas miR-17-92 inhibitors reduce cardiomyocyte proliferation in vitro and ex vivo.
miR-17-92 Represses Phosphatase and Tensin Homolog to Induce Cardiomyocyte Proliferation
We tested the expression of putative miR-17-92 targets that are known to play a role in cell proliferation. 20 We reasoned that the expression of these targets should be inversely correlated with the expression of miR-17-92, which is decreased in the hearts of miR-17-92 TG mice and increased in the hearts of miR-17-92 KO mice. Indeed, we found that the expression of several targets was elevated in the hearts of miR-17-92 KO mice ( Figure 5J ) and repressed in the hearts of miR-17-92 TG mice ( Figure 5K ). We focused on phosphatase and tensin homolog (PTEN), a tumor suppressor and a member of family of protein tyrosine phosphatases, [21] [22] [23] which was most dramatically altered in the hearts of miR-17-92 transgenic and mutant mice ( Figure 5J and 5K) . PTEN was reported a direct target of miR-19a/b, 24 the most potent member of the miR-17-92 cluster to induce tumor growth 24 and to promote cardiomyocyte proliferation in our study ( Figure 5A-5D ). Deletion of PTEN led to axon regeneration in central neural system, further highlighting the role of PTEN in cell proliferation and regeneration. 25 We asked whether PTEN could mediate the function of miR-19a/b in cardiomyocyte proliferation, and more specifically, we tested whether overexpression of PTEN could suppress miR-19a/b-induced cardiomyocyte proliferation. We overexpressed PTEN in neonatal rat cardiomyocyte, using a modified RNA approach. 26 We achieved dose-dependent overexpression of PTEN protein in transfected cells (Online Figure XXI) . Overexpression of PTEN completely abolished miR-19a/binduced cardiomyocyte proliferation ( Figure 5L and 5M ).
Discussion
In this report, our genetic studies using miR-17-92 knockout and transgenic mice, together with results of in vitro cell culture, demonstrated that members of the miR-17-92 cluster are required for and sufficient to induce cardiomyocyte proliferation. We found that PTEN is one of the miR-17-92 targets that mediate the function of this cluster of miRNAs, at least in vitro in cultured cardiomyocytes, to regulate cardiomyocyte proliferation.
In sharp contrast to embryonic cardiomyocytes, which exhibit strong proliferative activity, the rate of cardiomyocyte proliferation and turnover in adult hearts is very low, and it is generally conceived that adult hearts retain very limited (if any) potential for regeneration. As a consequence, the intrinsic renewal rate is insufficient to reverse cardiomyocyte loss and to restore cardiac function under pathophysiological conditions. 27, 28 Numerous attempts have been made to overcome Figure 5 . miR-17-92 regulates cardiomyocyte proliferation and represses the expression and function of phosphatase and tensin homolog (PTEN). A, Primary neonatal (P1) rat cardiomyocytes were transfected with indicated microRNA (miRNA) mimics or control mimics and cells were incubated with 5-ethynyl-2′-deoxyuridine (EdU; 10 μmol/L). One day later, cultures were fixed and stained with antibodies for EdU. cTNT marks cardiomyocytes. DAPI stains nuclei. Arrowheads point to EdU-positive cardiomyocytes. Bars=70 μm. B, P1 rat cardiomyocytes were transfected with indicated miRNA inhibitors or control inhibitor, and cells were incubated with EdU. One day later, cultures were fixed and stained with antibodies for EdU. cTNT marks cardiomyocytes. DAPI stains nuclei. Arrowheads point to EdUpositive cardiomyocytes. Bars=70 μm. C, Quantification of percentages of EdU + cardiomyocytes in cultured neonatal rat cardiomyocytes after being treated with miRNA mimics or control. D, Quantification of percentages of EdU + cardiomyocytes in cultured neonatal rat cardiomyocytes after being treated with miRNA inhibitors or control. E, P1 rat cardiomyocytes were transfected with miR-19a/b mimics or control mimic. One day later, cultures were fixed and stained with antibodies for aurora B (green). cTNT (red) marks cardiomyocytes. this hurdle, and one of the approaches is to induce cell-cycle activity in the surviving cardiomyocytes. 27, 29 Previous reports indicate that targeted overexpression of members of the cyclin D, cyclin D2 in particular, is sufficient to induce cardiomyocyte cell-cycle activity in adult hearts, resulting in improved cardiac function on myocardial injury. [30] [31] [32] Despite the fact that we know the critical role of the cell-cycle regulators in cardiomyocyte proliferation, the molecular pathways that diminish adult cardiomyocyte proliferation remain largely unknown. Our studies reported here, using genetic approaches, demonstrated that miRNAs are previously unidentified regulators of cardiomyocyte proliferation. Interestingly, a recent study reported that family of miR-15 inhibits cardiomyocyte proliferation in a manner that inhibition of it increases myocyte proliferation in adult hearts after myocardial infarction. 33 The potential of applying miRNAs to reconstitute lost cardiomyocytes in injured hearts could be of considerable therapeutic value for human cardiovascular disease.
Whereas miR-17-92 is required for normal animal development, cell proliferation, and tumor growth, individual members of the miR-17-92 cluster seem to possess distinct functions. 8, 14, 15 For example, miR-17 was shown to reduce cell proliferation. Transgenic overexpression of miR-17 resulted in growth retardation in animals. 34 It was recently reported that overexpression of miR-92a blocks angiogenesis in vitro and in vivo. 35 Additional studies found that miR-19 is a key component of the miR-17-92 cluster to induce cell proliferation and oncogenic growth. 24 Our results demonstrate that miR-19a/miR-19b are sufficient and required for neonatal cardiomyocyte proliferation in vitro, consistent with the view that miR-19 is a key component of the miR-17-92 cluster in controlling cell proliferation. In the future, it will be important to determine whether miR-19a/miR-19b promote cardiomyocyte proliferation in vivo, in particular in postmitotic adult cardiomyocytes.
We found that PTEN is a functional target of miR-17-92 cluster. More specifically, we showed that PTEN mediates the function of miR-19a/b in the regulation of cardiomyocyte proliferation. PTEN is a tumor suppressor, which was previously shown to be repressed by miR-17-92 during tumor growth. 24 Genetic deletion of PTEN in the heart led to hypertrophic growth. 36 Additional investigation revealed that loss of PTEN protects the heart from the development of pathological hypertrophy and heart failure under biomechanical stress, further highlighting the critical involvement of PTEN in cardiac function and disease. 30 Our studies link the function of miRNAs and PTEN in cardiomyocyte proliferation. Future studies will be important to illustrate how the miR-17-92-PTEN axis participates in cardiac regeneration.
In summary, our findings uncovered that miR-17-92 plays a key role in the regulation of cardiomyocyte proliferation in embryonic, postnatal, and adult hearts, implying the therapeutic potential of miR-17-92 in human cardiomyocyte proliferation, cardiac repair, regeneration, and related disorders.
